Parps in immune response: Potential targets for cancer immunotherapy
- 16 February 2025
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 234, 116803
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 153 references indexed in Scilit:
- Clinical trials of immunotherapy in triple-negative breast cancerBreast Cancer Research and Treatment, 2022
- PARP-1 regulates inflammasome activity by poly-ADP-ribosylation of NLRP3 and interaction with TXNIP in primary macrophagesCellular and Molecular Life Sciences, 2022
- Aryl hydrocarbon receptor (AHR) functions in infectious and sterile inflammation and NAD+-dependent metabolic adaptationArchives of Toxicology, 2021
- PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancerCancer Medicine, 2021
- FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian CancerThe Oncologist, 2020
- Long noncoding RNA SNHG16 promotes the tumorigenicity of cervical cancer cells by recruiting transcriptional factor SPI1 to upregulate PARP9Cell Biology International, 2019
- Robust immunoglobulin class switch recombination and end joining in Parp9‐deficient miceEuropean Journal of Immunology, 2017
- Small Molecule Microarray Based Discovery of PARP14 InhibitorsAngewandte Chemie International Edition, 2016
- Cancer Vaccines: A Brief Overview2016
- A Brief Outline of the Immune System2014